Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NDST2 small interfering RNA (siRNA) is a double-stranded RNA molecule designed to silence the expression of the N-deacetylase and N-sulfotransferase 2 (NDST2) gene through the RNA interference (RNAi) pathway. NDST2 is a Golgi-resident enzyme responsible for the N-deacetylation and N-sulfation of glucosamine residues during the biosynthesis of heparan sulfate proteoglycans (HSPGs). These HSPGs are critical components of the extracellular matrix and cell surface that modulate various signaling pathways involved in cell growth, migration, and tumor progression. In the context of hepatocellular carcinoma (HCC), NDST2 has been identified as a downstream target of the transcription factor FOXP4. Research indicates that NDST2 is upregulated in residual HCC cells following incomplete thermal ablation, contributing to malignant transformation and progression. Experimental use of NDST2 siRNA has demonstrated that knocking down this enzyme can inhibit the proliferation, migration, and invasion of liver cancer cells, suggesting that targeting the FOXP4/NDST2 axis may be a viable therapeutic strategy to prevent recurrence after ablation therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NDST2 small interfering RNA.